Bordeaux-based FineHeart, a clinical-stage medical technology company specializing in the development of solutions for cardiology, announced the completion of a €35 million first closing of its Series C financing round.
FineHeart said this funding is a key lever for activating European public funding, IPCEI Tech4Cure1, and for establishing its role as a European Active Implantable Medical Devices (AIMDs) leader.
“In total, FineHeart has secured €83 million in financing combining private capital and non-dilutive European public funding to accelerate the industrialization and clinical development of FlowMaker and establish itself as a future European AIMD leader …” said the company.
“This first €35 million closing brings together new investors, including Groupe Pasteur Mutualité and Groupe Etchart, alongside significant participation from the European Innovation Council (EIC)’s EIB fund. Existing investors — FH Founders (the founders’ holding company bringing together primarily international private investors from healthcare and entrepreneurship), Lurra, IRDI, Groupe Doliam and NACO — renew their confidence and support this next FlowMaker development phase …
“In parallel, FineHeart is to benefit from €48 million in grants from the IPCEI Tech4Cure program, disbursed in several tranches, in its role as the lead partner in the project to structure the European AIMD sector …”
Arnaud Mascarell, CEO and co-founder of FineHeart, said: ” We are delighted to welcome new investors at this first closing. I would like to extend my special thanks to Groupe Pasteur Mutualité and the European Innovation Council (EIC) for their key contributions, as well as to our long-standing shareholders, led by FH Founders, for their unwavering support.
“Together with the IPCEI, this funding strengthens our ambition to build disruptive, IP-protected technologies that enable more predictive, personalized, preventive, and participatory medicine—while advancing Europe’s industrial competitiveness and healthcare sovereignty.”
Svetoslava Georgieva, Chair of the EIC Fund Board, said: “We are convinced by FineHeart’s unique value proposition, which has all the assets required to become a major reference in health innovation in Europe.
“Its integrated breakthrough technology represents a strategic pillar for building European sovereignty in the field of AI-enabled medical devices.
“Supporting FineHeart’s scale-up from clinical development to industrial deployment fully aligns with the EIC’s mission: to foster the emergence of world-class European leaders.”